Benicar Users Reach $300 Million Settlement with Daiichi Sankyo
A Japanese pharmaceutical company, Daiichi Sankyo, has agreed to pay $300 million to settle claims that the high blood pressure drugs Benicar, Benicar HCT, Acor and Tribenzor can cause gastrointestinal illness. The Abbott Law Group lawyers have fought hard for our clients and this is a great news for thousands of patients who suffered severely adverse side effects.
The settlement was reached in the federal multidistrict litigation (MDL) case titled In re: Benicar
(Olmesartan) Products Liability Litigation, MDL 2606, pending in the U.S. District Court for the
District of New Jersey, Camden Division.
Under the settlement, all patients who made a claim and meet specified criteria, will be eligible for compensation.
To learn more, visit the official website for the Olmesartan Products Resolution.